Abstract:The development of innovative targeted therapeutic approaches are expected to surpass the efficacy of current forms of treatments and cause less damage to healthy cells surrounding the tumor site. Since the first development of targeting agents from hybridoma's, monoclonal antibodies (mAbs) have been employed to inhibit tumor growth and proliferation directly or to deliver effector molecules to tumor cells. However, the full potential of such a delivery strategy is hampered by the size of mAbs, which will obstruct the targeted delivery system to access the tumor tissue. By serendipity, a new kind of functional homodimeric antibody format was discovered in camelidae, known as heavy-chain antibodies (HCAbs). The cloning of the variable domain of HCAbs produces an attractive minimal-sized alternative for mAbs, referred to as VHH or nanobodies (Nbs). Apart from their dimensions in the single digit nanometer range, the unique characteristics of Nbs combine a high stability and solubility, low immunogenicity and excellent affinity and specificity against all possible targets including tumor markers. This stimulated the development of tumor-targeted therapeutic strategies. Some autonomous Nbs have been shown to act as antagonistic drugs, but more importantly, the targeting capacity of Nbs has been exploited to create drug delivery systems. Obviously, Nb-based targeted cancer therapy is mainly focused toward extracellular tumor markers, since the membrane barrier prevents antibodies to reach the most promising intracellular tumor markers. Potential strategies, such as lentiviral vectors and bacterial type 3 secretion system, are proposed to deliver target-specific Nbs into tumor cells and to block tumor markers intracellularly. Simultaneously, Nbs have also been employed for <i>in vivo</i> molecular imaging to diagnose diseased tissues and to monitor the treatment effects. Here, we review the state of the art and focus on recent developments with Nbs as targeting moieties for drug delivery systems in cancer therapy and cancer imaging.

Intracellular Delivery of Functional Native Antibodies under Hypoxic Conditions by Using a Biodegradable Silica Nanoquencher.

Intracellular Delivery of Native Proteins Facilitated by Cell-Penetrating Poly(disulfide)s.

Cell‐Penetrating Poly(disulfide) Assisted Intracellular Delivery of Mesoporous Silica Nanoparticles for Inhibition of Mir‐21 Function and Detection of Subsequent Therapeutic Effects

Highly efficient intracellular chromobody delivery by mesoporous silica nanoparticles for antigen targeting and visualization in real time

Cell-Permeant Bioadaptors for Cytosolic Delivery of Native Antibodies: A “Mix-and-Go” Approach

Silica Nanospheres Entrapped with Ultra-Small Luminescent Crystals for Protein Delivery

Hybrid Nanoparticles for Drug Delivery and Bioimaging: Mesoporous Silica Nanoparticles Functionalized with Carboxyl Groups and a Near-Infrared Fluorescent Dye.

A confined crosslinking strategy towards an intelligent organosilica-micellar hybrid drug delivery system

Polymeric coating lubricates nanocontainers to escape macrophage uptake for bioreceptor recognition

Liquid Droplet-Mediated Formulation of Lipid Nanoparticles Encapsulating Immunoglobulin G for Cytosolic Delivery

Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity

Fluorescent Protein-Based Multi-Functional Nanoparticles for Bioimaging and Drug Delivery

Construction of Antibody-Like Nanoparticles for Selective Protein Sequestration in Living Cells.

Entering and Lighting Up Nuclei Using Hollow Chitosan–Gold Hybrid Nanospheres

Redox-Responsive Molecularly Imprinted Nanoparticles for Targeted Intracellular Delivery of Protein Toward Cancer Therapy.

PEGylated denatured bovine serum albumin modified water-soluble inorganic nanocrystals as multifunctional drug delivery platforms

Fluorescent Protein Capped Mesoporous Nanoparticles For Intracellular Drug Delivery And Imaging

A Biomimetic Hybrid Nanoplatform for Encapsulation and Precisely Controlled Delivery of Theranostic Agents

Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy

Doxorubicin-tethered Fluorescent Silica Nanoparticles for Ph-Responsive Anticancer Drug Delivery